A 52-year-old man from rural India presents with a 6-month history of progressive dyspnea, chest pain, and recurrent cough productive of blood-tinged sputum. Chest X-ray shows bilateral upper lobe infiltrates with cavitation. Sputum smear microscopy is positive for acid-fast bacilli on three occasions. He is otherwise systemically well with no fever. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has microbiologically-confirmed pulmonary tuberculosis (sputum smear-positive on three occasions). The presentation is classic for chronic granulomatous inflammation caused by *Mycobacterium tuberculosis*. ## Why Immediate Anti-TB Therapy is Correct **Key Point:** In India, sputum smear-positive TB is treated empirically without awaiting drug susceptibility testing (DST) results, as per NTEP (National TB Elimination Programme) and WHO guidelines. Delay in therapy increases morbidity and mortality. **High-Yield:** The diagnostic threshold for TB treatment initiation in a sputum smear-positive patient is met. No further confirmatory investigations are required before starting HRZE (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol). **Clinical Pearl:** Sputum smear positivity on three separate occasions is diagnostic of active TB and indicates high infectivity. Treatment must commence immediately to prevent further transmission and disease progression. ## Management Algorithm ```mermaid flowchart TD A[Sputum smear-positive TB confirmed]:::outcome --> B{Start anti-TB therapy?}:::decision B -->|Yes - immediate| C[HRZE regimen initiated]:::action B -->|No - delay| D[Await DST results]:::urgent C --> E[Monitor clinical response at 2 weeks]:::action D --> F[Disease progression, transmission risk]:::urgent E --> G[Continue therapy, assess adherence]:::action ``` ## Why DST is Not the First Step **Warning:** DST results typically take 2–4 weeks (liquid media) or 6–8 weeks (solid media). Delaying therapy while awaiting DST in a smear-positive patient is contraindicated and increases the risk of treatment failure, relapse, and ongoing transmission. **Mnemonic:** **SPUTUM** — **S**mear-positive, **P**ositive culture = **T**reatment **U**rgently **M**ust start. DST is obtained in parallel but does not delay initiation. DST is performed on the initial sputum sample to guide therapy adjustment if the patient fails to respond or relapses, but it is not a prerequisite for starting treatment.